En

ABOUT HOOMYA

關于宏雅



深圳市賽百諾中加基因技術有限公司是(♦™₹₽shì)由臨床藥理(lǐ)學家(jiā)、我國(guó)遺傳藥理(lα <✘ǐ)學與藥物(wù)基因組學的(de)開(kāi)拓者和(hé)奠基人‌λ÷∞(rén)、個(gè)體(tǐ)化(huà)醫(yī)學的(de)£®→倡導者和(hé)引領者周宏灏院士及其團隊發起設立，緻₽γ力于個(gè)體(tǐ)化(huà)醫(y♦♥ī)學（精準醫(yī)學）檢測技(jì)ε®術(shù)的(de)研究與産業(yè)化✘Ω(huà)的(de)高(gāo)科(kē)技(jì)公司。公司主要(yào)↑☆從(cóng)事(shì)個(gè)體(tǐ)化(hu ∞∏₩à)醫(yī)學檢測産品（含産品科(kē)研、CDMO、儀器( ♦§qì)與設備、試劑耗材及檢測服務）的(de)開(kāi)發、運營與市(‌↓shì)場(chǎng)推廣，打造精準醫(y↕↓γαī)學時(shí)代的(de)專業(yè)個(g↓♦è)體(tǐ)化(huà)醫(yī)學檢測運營服務平台.

Hunan Hongya Gene Techno∑↕δlogy Co., Ltd. was founded by aca  ∞εdemician Zhou Honghao, a clinical pha↔↑rmacologist, pioneer and fo<©♥"under of pharmacogenetics and pharmδ★ acogenomics in my country, §ε∑ and advocate and leader of per "'≥sonalized medicine, and 'φ"his team. It is a high©≥♦-tech company dedicate≤♦∞d to the research an₽♠πλd industrialization of personaσ♦lized medicine (preci $÷≠sion medicine) testing technolo πgy. The company is mainly engage γ≠₽d in the development, operation and £λφ↑marketing of personalized medicine ≥✘testing products (including product​δ research, CDMO, instruments and ​φequipment, reagents and consumables, an§ε'd testing services), creating '$•a professional personalized medicine t∏↔esting operation service plat♦φ♠form in the era of p±♥recision medicine.





公司聯合以湘雅醫(yī)學檢驗所為(wèi)主體(tǐ)的(α÷<de)國(guó)內(nèi)外(wài)多(duō)家×↑(jiā)個(gè)體(tǐ)化(huà)醫(yī)學§​<→（精準醫(yī)學)專業(yè)研究機(jī)構，引進頂尖學者、 ε€ 美(měi)國(guó)墨菲特癌症中心醫(yī)學主任霍華德 · L · 麥克勞德為(wèi)代表的(de)專家(jiā)技(jì)術(s®↑hù)團隊，整合國(guó)內(nèi)外(wài)先進的(de)個(gèΩ  ↕)體(tǐ)化(huà)醫(yī)學檢測技(jì)術(shù)♠♦≈平台， 以研發帶動生(shēng)産和(hé)銷售，依托"✔具有(yǒu)先進性的(de)分(fēn)≠ ☆子(zǐ)診斷核心技(jì)術(shù)，在體(tǐ♣ )外(wài)診斷，尤其是(shì)高(g₹®₹™āo)端的(de)分(fēn)子(zǐ)診斷領域形成了←σ(le) 一(yī)系列具有(​ ₽↕yǒu)自(zì)主知(zhī)識産權的(de$>™")産品。
    The company has≥∏★ joined forces with a$β number of Personalized medicine (pr§÷$ecision medicine) professionσ←  al research institutes a π‍'t home and abroad, mainly base≥σ☆'d on the Xiangya med↓↔φical laboratory, howard L. McC ±≤loud, medical director of the↑"♣£ Murphy Cancer Center in the Unite≈±☆Ωd States and a leadi​β‌φng scholar, was brought in to rλ✘✘epresent the expert and technic☆↓al team to integrate advanced Perso‍§nalized medicine detα±$•ection technology platfo¶&rms at home and abroad, a series o≈¶f products with indepenσ₩®dent intellectual propert↑♦βy rights have been developed in'♠<β the field of in vitro diagnosis, espec ‍★"ially in high-end molecul♠∞'ar diagnosis.

公司目前主營業(yè)務包括各類應用(yòng)于"∑₹無創産前篩查、疾病預測、疾病早期篩查、疾病早期分(fē₹φ₹<n)子(zǐ)診斷與分(fēn) ₹λ♥ 子(zǐ)分(fēn)型、疾病個(gè)體(tǐ)化(huà)用(y®​òng)藥指導、疾病預後監測的(de)分(>"©fēn)子(zǐ)檢測産品，已形成覆蓋全國(gu® ó)的(de)營銷網絡，成為(wèi)個(gè)體(tǐ∑•☆)化(huà) 醫(yī)學（精準醫↔♦←(yī)學）專業(yè)服務領域的(de)優勢品牌企業(yè)。
   &n✔∏↓bsp;At present, the comp≥‍$≥any's main business includes varπ→♥ious applications in non-in÷•§σvasive prenatal screeni☆×Ωng, disease prediction, disease $ early screening, disease early molec±​÷∑ular diagnosis and classifica✘±βtion, the molecular detection produc✔σ™£ts of sub-typing, disease •↕individualized medication guid∞•≠ance and disease prognosis mo £•nitoring have formed a nati&↔onwide marketing network and become in∞§dividualized, medical (preci∏∑γ₽sion medicine) professional services in≥® the field of dominant bra‍✘>nd enterprises

技(jì)術(shù)團隊Technical Team

公司聯合以湘雅醫(yī)學檢驗所為(wèi)主體(tǐ)的(de)♥©國(guó)內(nèi)外(wài)多(duō)家(jiā)個(gè)≥ 體(tǐ)化(huà)醫(yī)學（精準醫(yī)學★ ✘®）專業(yè)研究機(jī)構，引進以 頂尖學者、美(měΩ i)國(guó)墨菲特癌症中心醫(yī)學主↕™  任霍華德 · L · 麥克勞德d為(wèi)代表的(de)專家(jiā)技(jì)術(shù)團隊，整合✘≈&₹ 國(guó)內(nèi)外(wài)™÷•先進的(de)個(gè)體(tǐ)化(huà)醫(y¥>ī)學檢測技(jì)術(shù)平台，以研發帶動生(shē €ng)産和(hé)銷售，依托具有(yǒu)先進性的( ↔de)分(fēn)子(zǐ)診斷核心技(jìπ≤)術(shù)， 在體(tǐ)外(wàiδ✔β)診斷，尤其是(shì)高(gāo)端的(de£↔)分(fēn)子(zǐ)診斷領域形成了(le)一(yīε≤Ω )系列具有(yǒu)自(zì)主知(zhī)識産權的(de)産品。
The company has teamed up ∞®δ♠with a number of Person&☆alized medicine (precision medi↓ δcine) professional research iΩ♥nstitutes at home and∏ק abroad, mainly based on the Xiangya £§ ±medical laboratory, howard L. McClou♣ $d D, medical director oαε±f the Murphy Cancer Center a✔π∏★nd a leading scholar, is the repre←£∑sentative of the expert and techn ←ε≥ical team, which integrates δ∑the advanced Persona∑®®₹lized medicine detection tec←♦≤'hnology platform at home and abαα↓road, in vitro diagnosis, espe‍★∞Ωcially in high-end molecular diagnosi←δs field, has formed a series of ↑'≠products with indepe¥φ‌↕ndent intellectual property r‌∏♦ights, relying on advanced ∏€molecular diagnosis core techn"✘Ω ology.

主營業(yè)務Business

公司目前主營業(yè)務包括各類應用(yòng)于無創産前篩查、疾病預♥≤→ε測、疾病早期篩查、疾病早期分(fēn)子(zǐ)診斷★<"↕與分(fēn)子(zǐ) 分(fēn)₩♣'±型、疾病個(gè)體(tǐ)化(huà)用(yòng)藥指導、疾病預後監測的(∞≠σde)分(fēn)子(zǐ)檢測産品，業(yè)務版圖已遍布湖 γ(hú)南(nán)、湖(hú)北(běi)、江蘇、浙   ≥  江、安徽、上(shàng)海(hǎi)、北(běi)京、天津、←β♣★河(hé)南(nán)、河(hé)北(běi)、山(shān<÷)東(dōng)、山(shān)西(xī↑ >)、陝西(xī)、遼甯、廣東(dōng)、廣西(xī)、雲南(náλπ≤$n)、 貴州等地(dì)區(qū)。
At present, the company's mai₩ ₽>n business includes various applicat↕λions in non-invasive prenatal ×♦πscreening, disease predi≥×ction, disease early <λ"screening, disease early moleculαΩσ±ar diagnosis and molecular, ★★molecular testing products $α≠≠for typing, individualized mε ♦¶edication guidance, and disease proφ↕gnosis monitoring, the business s' cope has spread over Hunan, ©¥→Hubei, Jiangsu, Zhejiang, Anh♣₩​ui, Shanghai, Beijing, Tia∑∞→njin, Henan, Hebei, S₽>♣↑handong, Shanxi, Shaanxi, Liaoning∞", Guangdong, Guangxi, Yunnan,↓& Guizhou and other reg¶♣↔≠ions.

行(xíng)業(yè)領域Industry sector

個(gè)體(tǐ)化(huà)醫¶÷(yī)學Personalized Medicine 

個(gè)體(tǐ)化(huà)醫(yī)學是(shì)21世紀醫← ±(yī)學發展的(de)必然趨勢。随著(zhe)人(rén)類基因組計  ®∏(jì)劃的(de)完成和(hé)後基因組學的(de)深入研究， ≥‌ 越來(lái)越多(duō)的↔♣(de)緻病基因被定位，更多(duō)疾病發生(s ≥✘hēng)的(de)遺傳學基礎得(de)以÷♣€<闡明(míng)，與人(rén)類生(shēng)理(lǐ)、病理(lǐ€δ)以及藥物(wù)效應 和(hé)毒副反應相(xià✔☆ ng)關的(de)基因特征不(bù)斷被揭示，促≥☆φ使醫(yī)學模式由經典的(de)基于規律β'↔♠總結的(de)“标準化(huà)醫(yī)學”，向基 ≤™<于個(gè)體(tǐ)基因差異進行(xíng)的(de)“量體(tǐβ γ‌)裁衣”式的(de)“個(gè)體(tǐ)化(huà)醫(yī)學”轉變 $₽€。個(gè)體(tǐ)化(huà)醫(yī)學是(shìδ‍₹×)根據個(gè)體(tǐ)的(de)基因信息對(duì)疾病 ♠​↕π 進行(xíng)診斷、治療和(hé)風(₹‍₩‌fēng)險評估，使疾病的(de)診治更為(wèi) γ♠精确、高(gāo)效，顯著提升醫(yī)療質量。個(gè)體(β≠tǐ)化(huà)醫(yī)學目前發 展最為(wèi)成熟的(→β≥de)領域是(shì)個(gè)體(tǐ)化(huà)用(yòng‍ ☆)藥，即以每個(gè)患者的(de)基因信息為(wèi)基礎決定個<π (gè)人(rén)的(de)藥物(wù)‍★♠治療方案，從(cóng)基因 組成或表達的(de)差異來≥≤☆♥(lái)預測疾病的(de)治療效果或毒副作(zuò)用(yòng)，α♠對(duì)每個(gè)患者選擇最适宜的(de↓♥)藥物(wù)療法進行(xíng)治療。 個(gè)體(€≥tǐ)化(huà)醫(yī)學彌補了(le)循δ↔證醫(yī)學的(de)缺點，其治療更有(yǒγ♠‌u)針對(duì)性，可(kě)以按照(zhào)個(gè)體(tǐ)對(↓≈‌ duì)某種特定疾病易感性的(de)不(bù)同 或對(<<®λduì)某種特定治療反應性的(de)不(bù)同，把人(rén¥∏ δ)群分(fēn)為(wèi)不(bù)同的(de)亞群，進而><☆δ對(duì)患者進行(xíng)有(yǒu)效地(dì)預防或治療性幹預， ε• 節約醫(yī)療費(fèi)用•λ♥↕(yòng)和(hé)避免毒副反應Personalized medicine"× is an inevitable trend in the develo✔‍δ‌pment of medicine in the← ₽© 21st century.With the completion of t  ​he human genome project and in-depth✘∏ research on post-genom←←‍ics, more and more disease-causing geσ✔nes have been locate≤πd, and the genetic basis of more diseσε‍ases has been elucidated, which ¶≤≥is related to human physiology, patπ∏hology, drug effects and toxic ₽'™•side effects. Gene characteristics ar₩‍↕≠e constantly being revealed,☆β   prompting the medical model toα∏ change from the classic "st∞₽¥andardized medicine" based o♣σ∏n rule summaries to "tailor-mγ©ade" "individualized medicine"¥♠ " based on individual ge©π•netic differences.Personalized mλ‌edicine is the diagnosis, trea↕✘♦tment and risk assessment≤ασ× of diseases based oש&n individual genetic inφ‍formation, making the diag  nosis and treatment of diseas✘₩δes more accurate and eff•✔↓‌icient, and significant₹δπ≤ly improving the quality of ≥≠ medical care.The most mature field &λof personalized medi₩≤♦cine is personalized medici≠₽ne, which determines individual ≥δ÷drug treatment plans §πbased on each patient'。 π₩>

個(gè)體(tǐ)化(huà)醫(yī)學檢測Personalized Medicine

通(tōng)過利用(yòng)專業(yè)檢測儀器(qì)‍∑π₩平台和(hé)配套的(de)試劑、耗材，檢測與疾病的(de)發生(shēng) λ和(hé)用(yòng)藥相(xiàng)關基因的(d☆♥‌e)結構改變、表達 和(hé)代謝(xiè)變化(huà)等，進₩♥一(yī)步使用(yòng)數(shù)據庫、分(fēn)析模型、± "♥軟件(jiàn)等工(gōng)具對(duì)檢測結果進行(xíng)專業(∞ yè)分(fēn)析并對(duì)分(fēδ®∞n)析結果進行(xíng)專業(yè) 咨詢™'←§（針對(duì)受檢者及其醫(yī)生(shēng)），對(duì)疾Ω≠病進行(xíng)個(gè)性化(huà)的(de)預測、診斷、治療決 ♠策和(hé)檢測的(de)臨床檢測服務。